Over the past decade, the management of metastatic renal cell carcinoma (RCC) has
undergone rapid evolution, culminating in a significant improvement in prognosis with …

Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30%
of cases diagnosed at the advanced or metastatic stage. While single-agent vascular …

Background Results from the phase 3 CLEAR study showed that lenvatinib plus
pembrolizumab improved progression-free survival and overall survival compared with …

Conclusion Herein, we comprehensively review and refine the clinical hallmarks uniquely
associated with ICI therapies, which not only will rejuvenate our assessment of ICI …

The treatment of patients with renal cell carcinoma (RCC) is evolving rapidly, with promising
new regimens being developed and approved for patients with advanced disease …

Introduction Significant advances have been made in the first-line therapy of metastatic renal
cell carcinoma (mRCC) since the approval of immune-based combinations, including …

Simple Summary Today, most patients with metastatic renal cancer receive systemic
treatment with so-called immune-checkpoint inhibitors that shall activate a patient's immune …

Introduction The treatment landscape of metastatic renal cell carcinoma (RCC) has
significantly evolved in recent years with the advent and approval of multiple combinations …

Over the past 5 years, several new immunotherapy treatments have been tested for
metastatic renal cell carcinoma (mRCC). Clinical trials assessing combinations of different …

Introduction We have experienced several paradigm shifts and substantial changes in the
treatment of metastatic renal cell carcinoma (mRCC) over the last two decades. Combination …